Baidu
map

Lancet Infect Dis:全球目前有超过230万艾滋和丙肝的共感染患者

2016-03-11 佚名 生物谷

近日,一项来自布里斯托大学等机构的研究人员发现,目前全球大约有230万HIV感染者同时还是丙肝感染者(HCV),相关研究刊登于The Lancet Infectious Diseases杂志上。其中有超过一半患者(130万左右)都是注射吸毒者,本文研究发现,相比未感染HIV的个体而言,感染HIV的个体发生丙肝感染的可能性是前者的6倍,这就提示卫生组织个改善HIV/HCV共感染者的相应治疗政策。

近日,一项来自布里斯托大学等机构的研究人员发现,目前全球大约有230万HIV感染者同时还是丙肝感染者(HCV),相关研究刊登于The Lancet Infectious Diseases杂志上。其中有超过一半患者(130万左右)都是注射吸毒者,本文研究发现,相比未感染HIV的个体而言,感染HIV的个体发生丙肝感染的可能性是前者的6倍,这就提示卫生组织个改善HIV/HCV共感染者的相应治疗政策。

目前HIV和HCV感染是全球主要的健康问题,全世界大约有370万HIV感染者,同时大约有1.15亿慢性HCV患者,然而此前很少有研究进行HIV/HCV共感染的研究,本文研究或是首次对HIV/HCV共感染进行的相关研究。文章中研究者对783项医学研究进行回顾来对患者HIV/HCV共感染进行有效评估,研究者Philippa Easterbrook说道,本文研究不仅揭示了HIV患者感染HCV风险较高,而且还说明注射吸毒人群中发生着HCV的高度流行,至少在80%以上,因此这就需要扩大常规对HIV患者进行HCV感染的检测,尤其是高风险的个体,同时也应当开发新型高治愈性的HCV疗法。

研究者Lucy Platt表示,改善对HCV和HIV患者的监督可以有效帮助解释两种病毒共感染的机体,并且为开发新型的检测、预防及相关疗法提供帮助。本文研究揭示了注射毒品如何驱动HIV感染者中HCV的流行,尤其是东欧及中亚国家人群;同时研究者还提出了需要扩大预防性的干预策略,比如针头、注射器以及阿片替代疗法等,其都可以有效降低共感染的发生。

本文研究重点关注了HCV抗体的流行,即研究者测定了HCV的暴露但并不测定病毒的活动性感染情况,测定活动性病毒的存在以及对疗法的需求或许需要更加昂贵的病毒检测技术,大约有20%-30%暴露于HCV的个体在后期机体的抗体会自动清除病毒。文章中研究者揭示了HIV/HCV共感染对东欧及中亚国家的巨大负担,据估计在这些地区有607700名共感染患者(27%的比例),尤其是在注射吸毒者中居多,撒哈拉沙漠以南非洲地区占到了所有病例中的19%,大约429600个共感染者。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-09-23 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-03-14 古天乐

    未来的方向,不知道是否会进一步发展

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-03-14 古天乐

    未来的方向,不知道是否会进一步发展

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-03-14 古天乐

    未来的方向,不知道是否会进一步发展

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-03-12 xuzhiqiang

    这么多人

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-03-12 忠诚向上

    好好学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2012080, encodeId=60372012080c5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Oct 05 01:16:00 CST 2016, time=2016-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066316, encodeId=bf1b206631606, content=<a href='/topic/show?id=77be30014f4' target=_blank style='color:#2F92EE;'>#共感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30014, encryptionId=77be30014f4, topicName=共感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Apr 28 22:16:00 CST 2016, time=2016-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828430, encodeId=97001828430dc, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Sep 23 11:16:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69431, encodeId=fff069431ff, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:55:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69428, encodeId=3eb76942862, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69429, encodeId=a0346942949, content=未来的方向,不知道是否会进一步发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160314/IMG56E64D2A545669487.jpg, createdBy=4ff71699844, createdName=古天乐, createdTime=Mon Mar 14 17:43:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68744, encodeId=181768e4466, content=这么多人, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLtHjk2DMULKiaQuuL9IZ32xvowd7zkDZh8dnRPekicGbHbRReRbvicmYffuezVtVHFPYTdNA32Hg9Hg/132, createdBy=1c621623554, createdName=xuzhiqiang, createdTime=Sat Mar 12 21:57:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68686, encodeId=646d6868631, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Mar 12 15:52:00 CST 2016, time=2016-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=68669, encodeId=4fc768669ce, content=珍爱生命吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00531550470, createdName=layyjiangli, createdTime=Sat Mar 12 09:09:00 CST 2016, time=2016-03-12, status=1, ipAttribution=)]
    2016-03-12 layyjiangli

    珍爱生命吧!

    0

相关资讯

Gastroenterology:感染HCV对心血管疾病风险的影响

先前关于HCV和心血管风险的研究结果具有争议,因此研究者检索了PubMed Central、Medline、Embase等数据库上比较HCV患者和非HCV患者心血管发生率,或心血管疾病患者HCV发生率相关文献,进行荟萃分析HCV感染对心血管疾病相关发病率和死亡率的影响。最终纳入了22项研究,由3名研究人员独立提取数据,使用随机效应模型进行荟萃分析。研究结果显示,与非HCV感染的患者相比,感染HCV

Hepatology:他汀类药物可帮助HCV患者降低肝硬化和HCC风险

他汀类药物可延迟慢性丙型肝炎(HCV)患者肝纤维化进展、降低肝细胞性肝癌(HCC)风险。但是最有效的他汀类类型和剂量是什么?研究者进行了一项研究,探究不同类型和剂量的他汀类药物对HCV患者肝纤维化和HCC的影响。研究者通过电子检索的丙肝病毒感染的退伍军人(ERCHIVES)数据库获取了2001-2014年使用抗HCV治疗的所有患者,以及肝硬化和HCC信息。使用累积限定日剂量(cDDD)测定他汀类药

Lancet infect dis:HIV合并HCV感染的负担(全球性meta分析)

原始出处:Lucy Platt,Philippa Easterbrook,et al, Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis,lancet infect disease,24 February 2016http

Hepatology:DCV-SOF-RBV治疗HCV基因型3感染的晚期肝脏疾病患者(ALLY-3+)

基因型3的(丙型肝炎病毒)HCV感染常常会导致进展期肝病,当前迫切需要有效的治疗。先前有研究表明,达卡他韦(DCV:泛基因型NS5A抑制剂)和索非布韦(SOF:核苷酸NS5B抑制剂)联合治疗非肝硬化HCV基因型3的感染长达12周,有效性达96%。ALLY-3+ Ⅲ期研究评估了DCV-SOF和利巴韦林(RBV)对晚期纤维化(n = 14)或代偿期肝硬化(n = 36)的HCV基因型3感染患者的疗效,

Hepatology:三种药物联合治疗肝硬化或肝移植的HCV感染者(ALLY-1)

对慢性丙型肝炎病毒(HCV)感染伴晚期肝硬化或肝移植术后复发的患者,当前并没有针对所有HCV基因型的有效治疗方案。研究者进行了一项研究(ALLY-1),评估每天一次达卡他韦60 mg(泛基因型NS5A抑制剂)+索非布韦400 mg(NS5A抑制剂)+利巴韦林600 mg,对慢性HCV(任何基因型)感染伴肝硬化(代偿或失代偿)或肝移植术后复发的患者的疗效(12周的治疗时间,24周的随访时间)。移植患

Hepatology:≥65的HCV感染者,仍可使用LDV/SOF治疗

研究者进行了一项研究,比较< 65岁 vs. ≥ 65岁人群中雷迪帕韦/索非布韦(LDV/SOF)治疗丙型肝炎(HCV)基因型1感染的安全性和有效性。 比较两组间的12周的持续病毒学应答(SVR12)、治疗相关不良事件(AEs)和实验室异常指标。研究共纳入2293名患者,其中264 (12%)名患者≥ 65岁,24名患者≥ 75岁。研究数据显示,< 65岁和≥ 65岁组SVR12分别为

Baidu
map
Baidu
map
Baidu
map